Lung Cancer: is a cancer that ignites in the lungs and most often exist in people who smoke. Two major types of lung cancer are non-small cell lung cancer and small cell lung cancer. The roots of lung cancer include smoking, secondhand smoke, exposure to certain toxins, and family history. The treatments vary but may include surgery, chemotherapy, targeted drug therapy, radiation therapy, and immunotherapy.
The immune system is capable of recognizing tumors and eliminates many early malignant cells. However, tumors evolve to evade immune attack, and the tumor microenvironment is immunosuppressiv...
FTIR spectroscopic imaging is an emerging tool for label-free, non-destructive characterization of tissues. The pathological annotation of tissue can be performed in an automated and objectiv...
The talk will first report on a new patented method of counting CTCs based on the metabolism of tumor cells, that favors acidification of their near environment. In order to maintain the acid...
Melanoma arises in the pigment producing cells (melanocytes) and is the deadliest of the skin cancers. It accounts for nearly 200,000 new cases of cancer each year worldwide and in the U.S. o...
DATE: September 22, 2016
TIME: 4:00am PT, 7:00am ET, 11:00am GMT
Here, we present a novel approach that combines the principles of the western blot (protein separation by SDS-PAGE; ...
DATE: June 30, 2016
TIME: 8:00am Pacific time, 11:00am Eastern time
Focusing solely on malignant cancer cells and the genes that they express is modestly just a glimpse of the...
Wolframin is a major protein of the endoplasmic reticulum, it is expressed in most tissues and clinical data demonstrate its significant connection to diabetes mellitus. L...
Pathology departments are under significant pressure to meet the demands of a precise medicine environment where general phenotypic attributes are no longer sufficient for accurately defining...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
The advent of personalized medicine employing molecular targeted therapies has markedly changed the treatment of cancer in the past 10 years. Although tumor tissue biopsy-based genotyping is...
Over the past decade, there has been a rapid growth in studies of secreted membrane vesicles, collectively called extracellular vesicles (EVs). (1) The release of EVs has been reported in the...
DATE: November 4th, 2015
TIME: 11:00am Pacific time, 2:00pm Eastern time
AMPK, a highly conserved sensor of cellular energy status, is found in all eukaryotic cells and maintains met...
Hepatocellular carcinoma (HCC) is a significant contributor to cancer-related mortality in the United States and worldwide. Current treatments are largely ineffective: single agent and combin...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
DATE: September 9, 2015TIME: 9:00am PDT, 12:00PM EDTDriver mutations are causally implicated in tumorigenesis and disease progression, and they are defined by molecular abnormalities such as ...
Genome Wide Association Studies (GWAS) and eQTL analyses are producing huge numbers of associations and show no signs of slowing. There are now more than 8,500 SNPs associated with more than...
Every cell in the body can release several types of extracellular vesicles (EVs), often called ”exosomes” or ”microvesicles”. These vesicles carry a wide array of mole...
Fusion genes play a central role in many cancer types. They have been used to classify malignancy, risk factors, disease prognosis, and companion diagnostic biomarkers for certain approved dr...
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...
Patients with chromosomal rearrangements resulting in fusion proteins are among the most responsive to published targeted therapy. For example, targeting of the EML4-ALK fusion in non-small c...
In this presentation I describe pathway based analyses of genotyping data to identify pathways related to the development of complex diseases, with a focus on lung cancer and selected autoimm...
A recent publication in Nature Genetics1 analyzed TCGA data, and classified solid tumors into two mutually exclusive classes: C class tumors, driven by copy number alterations; and M class tu...
Non Small Cell Lung Cancer (NSCLC) is one of the most significant causes of cancer-related mortality worldwide. In about 6-7% of NSCLC, rearrangements involving the Anaplastic Lymphoma Kinase...
The immune system is capable of recognizing tumors and eliminates many early malignant cells. However, tumors evolve to evade immune attack, and the tumor microenvironment is immunosuppressiv...
FTIR spectroscopic imaging is an emerging tool for label-free, non-destructive characterization of tissues. The pathological annotation of tissue can be performed in an automated and objectiv...
The talk will first report on a new patented method of counting CTCs based on the metabolism of tumor cells, that favors acidification of their near environment. In order to maintain the acid...
Melanoma arises in the pigment producing cells (melanocytes) and is the deadliest of the skin cancers. It accounts for nearly 200,000 new cases of cancer each year worldwide and in the U.S. o...
DATE: September 22, 2016
TIME: 4:00am PT, 7:00am ET, 11:00am GMT
Here, we present a novel approach that combines the principles of the western blot (protein separation by SDS-PAGE; ...
DATE: June 30, 2016
TIME: 8:00am Pacific time, 11:00am Eastern time
Focusing solely on malignant cancer cells and the genes that they express is modestly just a glimpse of the...
Wolframin is a major protein of the endoplasmic reticulum, it is expressed in most tissues and clinical data demonstrate its significant connection to diabetes mellitus. L...
Pathology departments are under significant pressure to meet the demands of a precise medicine environment where general phenotypic attributes are no longer sufficient for accurately defining...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
The advent of personalized medicine employing molecular targeted therapies has markedly changed the treatment of cancer in the past 10 years. Although tumor tissue biopsy-based genotyping is...
Over the past decade, there has been a rapid growth in studies of secreted membrane vesicles, collectively called extracellular vesicles (EVs). (1) The release of EVs has been reported in the...
DATE: November 4th, 2015
TIME: 11:00am Pacific time, 2:00pm Eastern time
AMPK, a highly conserved sensor of cellular energy status, is found in all eukaryotic cells and maintains met...
Hepatocellular carcinoma (HCC) is a significant contributor to cancer-related mortality in the United States and worldwide. Current treatments are largely ineffective: single agent and combin...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
DATE: September 9, 2015TIME: 9:00am PDT, 12:00PM EDTDriver mutations are causally implicated in tumorigenesis and disease progression, and they are defined by molecular abnormalities such as ...
Genome Wide Association Studies (GWAS) and eQTL analyses are producing huge numbers of associations and show no signs of slowing. There are now more than 8,500 SNPs associated with more than...
Every cell in the body can release several types of extracellular vesicles (EVs), often called ”exosomes” or ”microvesicles”. These vesicles carry a wide array of mole...
Fusion genes play a central role in many cancer types. They have been used to classify malignancy, risk factors, disease prognosis, and companion diagnostic biomarkers for certain approved dr...
Survival rates for early stage non-small cell lung cancer (NSCLC) remain unacceptably low compared to other common solid tumors. This mortality reflects a weakness in conventional staging, as...
Patients with chromosomal rearrangements resulting in fusion proteins are among the most responsive to published targeted therapy. For example, targeting of the EML4-ALK fusion in non-small c...
In this presentation I describe pathway based analyses of genotyping data to identify pathways related to the development of complex diseases, with a focus on lung cancer and selected autoimm...
A recent publication in Nature Genetics1 analyzed TCGA data, and classified solid tumors into two mutually exclusive classes: C class tumors, driven by copy number alterations; and M class tu...
Non Small Cell Lung Cancer (NSCLC) is one of the most significant causes of cancer-related mortality worldwide. In about 6-7% of NSCLC, rearrangements involving the Anaplastic Lymphoma Kinase...
Follow
